Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?
Kenneth Dickstein
Correspondence University of Bergen, Cardiology Division, Stavanger University Hospital, Stavanger, Norway
Email trout@online.no
This article has no abstract so we have provided the first paragraph of the full text.
Interventions to attenuate pathological matrix turnover and remodeling with ACE inhibitors and angiotensin-receptor blockers have improved survival and reduced morbidity in patients following MI.1, 2 An intervention designed to further reduce remodeling and improve patient outcomes during long-term follow-up requires evaluation of a large sample of high-risk patients, as any incremental benefit would be small.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
